Ticker Details
Prelude Therapeutics Inc.
IPO Date:	September 25, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$529.1M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.52 | 4.91%
Avg Daily Range (30 D):	$0.20 | 4.18%
Avg Daily Range (90 D):	$0.23 | 4.89%

Institutional Daily Volume
Avg Daily Volume:	.26M
Avg Daily Volume (30 D):	.39M
Avg Daily Volume (90 D):	.39M

Trade Size
Avg Trade Size (Sh.):	123
Avg Trade Size (Sh.) (30 D):	83
Avg Trade Size (Sh.) (90 D):	85

Institutional Trades
Total Institutional Trades:	344
Avg Institutional Trade:	$1.98M
Avg Institutional Trade (30 D):	$2.58M
Avg Institutional Trade (90 D):	$2.55M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.38M
Avg Closing Trade (30 D):	$11.97M
Avg Closing Trade (90 D):	$3.32M
Avg Closing Volume:	113.42K

News

Apr 20, 2026 @ 10:00 AM Prelude Therapeutics Presents Preclinical Data fro... Source: Na

Dec 6, 2025 @ 4:00 PM Prelude Therapeutics Presents Data at the 2025 ASH... Source: Prelude Therapeutics

Aug 14, 2025 @ 11:23 AM Prelude Cuts Q2 Losses and Costs 13% Source: Jesterai

Sep 13, 2024 @ 2:00 PM Prelude Therapeutics’ SMARCA2 Degrader PRT3... Source: Prelude Therapeutics Incorporated

Jun 3, 2024 @ 11:01 AM Prelude Therapeutics to Participate in Upcoming He... Source: Prelude Therapeutics, Inc.

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.73	$-.14	$-.13
Diluted EPS	$-.73	$-.14	$-.13
Revenue	$22.42M	$5.7M	$4.58M
Gross Profit
Net Income / Loss	$-60.49M	$-13.92M	$-10.39M
Operating Income / Loss	$-67.4M	$-15.45M	$-14.18M
Cost of Revenue
Net Cash Flow	$-.06M	$4.74M	$-13.5M
PE Ratio